LitAlert ~~

    • Update: FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer.
    • [No author given]
    • FORCE. 2020 Jul 7.

    Original research:

    Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    • Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
    • Desai NV, Tung NM.
    • Breast J. 2020 Jul 6. doi: 10.1111/tbj.13972. Online ahead of print.
    • Review
    • Sequence Now, Later, or Never?
    • Hagemann IS.
    • Clin Chem. 2020 Jul 1;66(7):883-885. doi: 10.1093/clinchem/hvaa053.
    • Case report


    Commentary on Sequence Now, Later, or Never?

    • Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.
    • Malhotra H, Kowtal P, Mehra N, Pramank R, Sarin R, Rajkumar T, Gupta S, Bapna A, Bhattacharyya GS, Gupta S, Maheshwari A, Mannan AU, Reddy Kundur R, Sekhon R, Singhal M, Smruti BK, Sp S, Suryavanshi M, Verma A.
    • JCO Glob Oncol. 2020 Jul;6:991-1008. doi: 10.1200/JGO.19.00381.
    • Small Steps in Pancreatic Cancer – Episode 2: Relatives at Risk.
    • McAllister F, Maitra A, Burton M, McGuire M..
    • Medscape. 2020 Jun 25.
    • Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.
    • Gromisch C, Qadan M, Albuquerque Machado M, Liu K, Colson Y, Grinstaff MW.
    • Cancer Res. 2020 Mar 27:canres.2731.2019. doi: 10.1158/0008-5472.CAN-19-2731. Epub ahead of print.
    • Review